These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 33721181)

  • 1. Targeting Histone Modifications in Bone and Lung Metastatic Cancers.
    Edwards CM; Johnson RW
    Curr Osteoporos Rep; 2021 Jun; 19(3):230-246. PubMed ID: 33721181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
    Collier CD; Getty PJ; Greenfield EM
    Adv Exp Med Biol; 2020; 1258():55-75. PubMed ID: 32767234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential molecular mechanistic behavior of HDACs in cancer progression.
    Singh T; Kaur P; Singh P; Singh S; Munshi A
    Med Oncol; 2022 Aug; 39(11):171. PubMed ID: 35972597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of histone deacetylases (HDACs) in human cancer.
    Ropero S; Esteller M
    Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting histone deacetylases for cancer therapy: from molecular mechanisms to clinical implications.
    Li Z; Zhu WG
    Int J Biol Sci; 2014; 10(7):757-70. PubMed ID: 25013383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy.
    Patra S; Panigrahi DP; Praharaj PP; Bhol CS; Mahapatra KK; Mishra SR; Behera BP; Jena M; Bhutia SK
    Cell Mol Life Sci; 2019 Sep; 76(17):3263-3282. PubMed ID: 30982077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting tumor angiogenesis with histone deacetylase inhibitors.
    Ellis L; Hammers H; Pili R
    Cancer Lett; 2009 Aug; 280(2):145-53. PubMed ID: 19111391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
    Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
    Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
    Ranganna K; Selvam C; Shivachar A; Yousefipour Z
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
    Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
    Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
    von Burstin J; Eser S; Paul MC; Seidler B; Brandl M; Messer M; von Werder A; Schmidt A; Mages J; Pagel P; Schnieke A; Schmid RM; Schneider G; Saur D
    Gastroenterology; 2009 Jul; 137(1):361-71, 371.e1-5. PubMed ID: 19362090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?
    Petta V; Gkiozos I; Strimpakos A; Syrigos K
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):935-52. PubMed ID: 24036844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acids as histone deacetylase inhibitors: Old biochemistry tales in a new life sciences town.
    Ediriweera MK
    Drug Discov Today; 2023 May; 28(5):103569. PubMed ID: 36990144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer.
    Lian B; Chen X; Shen K
    Front Immunol; 2023; 14():1164514. PubMed ID: 36969235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.